Format

Send to

Choose Destination
Semin Liver Dis. 2015 Aug;35(3):338-48. doi: 10.1055/s-0035-1562951. Epub 2015 Sep 17.

Pharmacotherapy for Nonalcoholic Fatty Liver Disease.

Author information

1
Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, Indiana.

Abstract

Lifestyle modifications and optimization of the management of cardiometabolic comorbidities are currently the mainstay of treatment for patients with nonalcoholic fatty liver disease. Pharmacotherapy to halt or reverse hepatic histological injury and prevent the development of end-stage liver disease is specifically offered to patients with nonalcoholic steatohepatitis (NASH) and those with advanced fibrosis. In this review, the authors discuss the state of the art of various pharmacological agents for NASH. The efficacy of vitamin E and pioglitazone is reasonably well established in a selected group of patients with NASH. Current data do not offer convincing evidence for efficacy of pentoxifylline, long-chain polyunsaturated fatty acids, angiotensin receptor blockers, metformin, or ursodeoxycholic acid. They also discuss the state of several emerging agents for treating NASH including the farsenoid X receptor ligand, obeticholic acid.

PMID:
26378648
PMCID:
PMC5401764
DOI:
10.1055/s-0035-1562951
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Georg Thieme Verlag Stuttgart, New York Icon for PubMed Central
Loading ...
Support Center